Kane Biotech Stock Today
| KNBIF Stock | USD 0.03 0.00 0.00% |
PerformanceWeakest
| Odds Of DistressSmall
|
Kane Biotech is trading at 0.0266 as of the 2nd of January 2026. This is a No Change since the beginning of the trading day. The stock's lowest day price was 0.0266. Kane Biotech has about a 32 percent probability of financial distress in the next few years of operation and has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 3rd of December 2025 and ending today, the 2nd of January 2026. Click here to learn more.
Kane Biotech Inc., a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. Kane Biotech Inc. was incorporated in 2001 and is based in Winnipeg, Canada. The company has 124.83 M outstanding shares. More on Kane Biotech
Moving together with Kane Pink Sheet
| 0.87 | NONOF | Novo Nordisk AS | PairCorr |
| 0.88 | NVO | Novo Nordisk AS | PairCorr |
| 0.73 | CSLLY | CSL | PairCorr |
| 0.61 | CMXHF | CSL Limited | PairCorr |
Moving against Kane Pink Sheet
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Kane Pink Sheet Highlights
| President CEO | Mark AhrensTownsend |
| Business Concentration | Biotechnology, Healthcare (View all Sectors) |
Kane Biotech [KNBIF] is a Pink Sheet which is traded between brokers as part of OTC trading. The company currently falls under 'Micro-Cap' category with a current market capitalization of 10.45 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Kane Biotech's market, we take the total number of its shares issued and multiply it by Kane Biotech's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Kane Biotech classifies itself under Healthcare sector and is part of Biotechnology industry. The entity has 124.83 M outstanding shares.
Kane Biotech has accumulated about 2.53 M in cash with (2.29 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.02.
Check Kane Biotech Probability Of Bankruptcy
Ownership AllocationKane Biotech maintains a total of 124.83 Million outstanding shares. Kane Biotech holds significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Kane Ownership Details
Kane Biotech Risk Profiles
| Mean Deviation | 1.24 | |||
| Standard Deviation | 3.97 | |||
| Variance | 15.78 | |||
| Risk Adjusted Performance | (0.03) |
Kane Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Kane Biotech without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Fundamental Analysis Now
Fundamental AnalysisView fundamental data based on most recent published financial statements |
| All Next | Launch Module |
Kane Biotech Corporate Management
| Kevin Cole | Pres Inc | Profile | |
| Wendy Nachtigall | Director Marketing | Profile | |
| Gregory Schultz | Chief Board | Profile | |
| Lorne Gorber | Investor Relations | Profile | |
| Ray Dupuis | Chief Officer | Profile |
Other Information on Investing in Kane Pink Sheet
Kane Biotech financial ratios help investors to determine whether Kane Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Kane with respect to the benefits of owning Kane Biotech security.